Kymera治疗学获得“Buy”评分,尽管损失了Q1,但价格目标仍提高到60美元。 Kymera Therapeutics gets a "Buy" rating with price target raised to $60, despite a Q1 loss.

生物制药公司Kymera Therapeutics获得"购买"评级, 目标价格由HC Wainwright提高到60美元. Kymera Therapeutics, a biopharmaceutical company, received a "Buy" rating with a price target raised to $60 by HC Wainwright. 该公司报告的Q1损失比预期的要小,机构所有权增加16.01%。 The company reported a narrower-than-expected Q1 loss and saw a 16.01% increase in institutional ownership. 尽管财政量度为负数,但许多公司最近所作的分析表明,这有可能带来好处,Wells Fargo和Oppenheimer也提供了积极的前景,尽管价格目标略低。 Despite negative financial metrics, recent analyses from multiple firms suggest a potential upside, with Wells Fargo and Oppenheimer also providing positive outlooks, though slightly lower price targets.